AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04277533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)
Description: GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
Study NCT01096927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Clavulanic Acid
Description: 7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
Study NCT01634906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temporary discontinuation of statin therapy
Description: All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
Study NCT03085173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRt/19-28z/4-1BBL CAR T cells
Description: Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.
Study NCT00963157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
Study NCT00963157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
Study NCT01176448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated laser
Description: Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
Study NCT01176448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
Study NCT01552096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peritonsillar infiltration
Description: 1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
Study NCT01552096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peritonsillar infiltration
Description: 1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
Study NCT01552096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peritonsillar infiltration
Description: 1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
Study NCT03676803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed spices
Description: All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
Study NCT03676803 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule containing 5 g of maltodextrin
Description: placebo capsule containing 5 g of maltodextrin
Study NCT02910609 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Description: Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
Study NCT00655577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised, mainly home-based balance, strength and jumping exercises
Study NCT00655577 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise
Description: Supervised, mainly home-based balance, strength and jumping exercises
Study NCT00102908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Zoledronate infusion
Study NCT00102908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronate placebo
Description: Zoledronate placebo infusion
Study NCT02045121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indwelling Pleural Catheter
Study NCT02045121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Talc Pleurodesis
Study NCT02531984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study NCT02531984 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Study NCT03728842 — intervention group
Intervention type: OTHER
Intervention: Blood collection for laboratory studies
Description: Peripheral whole blood will be collected
Study NCT03728842 — intervention group
Intervention type: OTHER
Intervention: Data collection from medical record
Description: Clinical data such as demographics and cancer characteristics, history and treatment will be collected
Study NCT02319928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Study NCT02319928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Study NCT01297049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Description: All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
Study NCT00520741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
Study NCT00520741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: 50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
Study NCT03344510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetic Anesthesia Device
Description: A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
Study NCT03344510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: One injection will be administered without the kinetic anesthesia device.
Study NCT01328275 — intervention group
Intervention type: DRUG
Intervention: standard regimens according to the Thai Ministry of Public Health national guidelines
Description: Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Study NCT02554864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Local anesthetic
Study NCT02554864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Local anesthetic
Study NCT02625948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Study NCT02625948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT01060670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra® Dermal Regeneration Template
Description: Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
Study NCT01060670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Wound Therapy
Description: Conventional Wound Therapy
Study NCT01725451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae
Study NCT01725451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant Spray
Description: Administered topically to axillae
Study NCT01725451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant and Antiperspirant Combination Spray
Description: Administered topically to axillae
Study NCT01725451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant and Antiperspirant Combination Stick
Description: Administered topically to axillae
Study NCT04428567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Treadmill exercise + Cognitive Training
Description: The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
Study NCT05665582 — intervention group
Intervention type: OTHER
Intervention: Family program
Description: A 4-day psychoeducational family program.
Study NCT01648166 — intervention group
Intervention type: OTHER
Intervention: Environmental sampling
Description: Soil, water, blood, urine, hair and radon testing in homes in Appalachia
Study NCT01002690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 90 mg/day orally for 10-13 days
Study NCT02351726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitroflow DL
Description: Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
Study NCT00732290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel then fluoxetine+clopidogrel
Description: D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
Study NCT00732290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine+clopidogrel then clopidogrel
Description: D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
Study NCT03670238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orogastric intubation
Description: Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
Study NCT03670238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric intubation
Description: After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
Study NCT03988270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
Study NCT03333226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping (ARM)
Description: ARM lymph node preservation versus removal
Study NCT03333226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Reverse Mapping (ARM)
Description: ARM lymph node preservation versus removal
Study NCT02175797 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
Study NCT04260204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric cardiac surgery
Study NCT01601678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
Study NCT01601678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Heller Myotomy (LHM)
Description: Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
Study NCT03946501 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT00846625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: Intravitreal injection (4 mg/0.1 ml)
Study NCT00846625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection, 0.5 mg
Study NCT01725425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control is designed to determine average mood.
Study NCT01725425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase Portion Size
Description: The purpose is to determine whether a change in mood will occur.
Study NCT01725425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease Portion Size
Description: The purpose is to determine whether a change in mood will occur.
Study NCT01725425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Portions
Description: The purpose is to determine if a change in mood will occur.
Study NCT04303338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Masotherapy with neural tension and masotherapy with non-neural tension
Description: To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
Study NCT04303338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Masotherapy with neural tension and masotherapy with non-neural tension
Description: To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
Study NCT00663221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyans, Calcium and Vitamin D
Study NCT00663221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01191320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 1x daily for 3 months
Study NCT01191320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Capsules 12.5 mg or 25 mg 1x daily for 3 months
Study NCT02627742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MetaNeb® System
Description: The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
Study NCT00689013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized letter
Description: On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
Study NCT00689013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flyer advertisement
Description: Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
Study NCT00689013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newspaper press release
Description: During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
Study NCT04168346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose iv infusion
Study NCT04168346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NaCl 0.9% infusion
Study NCT03160352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
Study NCT02928913 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03296475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Wall Closure Force (N).
Description: This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
Study NCT04051970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral
Description: Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care.
Study NCT04051970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral
Description: Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care.
Study NCT02003183 — intervention group
Intervention type: RADIATION
Intervention: [F-18]FDDNP
Description: Each participant was injected with \[F-18\]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
Study NCT03256968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: ataluren